相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Nader Al Nakouzi et al.
EUROPEAN UROLOGY (2015)
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
Axel Heidenreich et al.
EUROPEAN JOURNAL OF CANCER (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
Carmel J. Pezaro et al.
EUROPEAN UROLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prostate cancer: ESMO Consensus Conference Guidelines 2012
A. Horwich et al.
ANNALS OF ONCOLOGY (2013)
Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
Susan Halabi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2013)
Drug rechallenge and treatment beyond progression-implications for drug resistance
Elizabeth A. Kuczynski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J. Mezynski et al.
ANNALS OF ONCOLOGY (2012)
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer
Matthias M. Heck et al.
BJU INTERNATIONAL (2012)
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity
M. Toulmonde et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors
Orazio Caffo et al.
UROLOGY (2012)
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
Giuseppe Di Lorenzo et al.
BJU INTERNATIONAL (2011)
Drug resistance in metastatic castration-resistant prostate cancer
Bostjan Seruga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
Ioannis Mountzios et al.
UROLOGY (2011)
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard et al.
BJU INTERNATIONAL (2010)
Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma Patients
Ivan N. Zama et al.
CANCER (2010)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
Yohann Loriot et al.
EUROPEAN JOURNAL OF CANCER (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
Norihito Soga et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
D. R. Berthold et al.
ANNALS OF ONCOLOGY (2008)
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer - Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
Tomasz M. Beer et al.
CANCER (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
S Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
